KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Finished Goods: 2016-2025

Historic Finished Goods for Sarepta Therapeutics (SRPT) over the last 9 years, with Sep 2025 value amounting to $64.8 million.

  • Sarepta Therapeutics' Finished Goods fell 16.90% to $64.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.8 million, marking a year-over-year decrease of 16.90%. This contributed to the annual value of $47.2 million for FY2024, which is 23.62% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Finished Goods of $64.8 million as of Q3 2025, which was down 8.71% from $71.0 million recorded in Q2 2025.
  • Sarepta Therapeutics' Finished Goods' 5-year high stood at $78.0 million during Q3 2024, with a 5-year trough of $26.7 million in Q4 2021.
  • Moreover, its 3-year median value for Finished Goods was $52.9 million (2024), whereas its average is $55.8 million.
  • In the last 5 years, Sarepta Therapeutics' Finished Goods soared by 713.44% in 2021 and then declined by 23.62% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Finished Goods stood at $26.7 million in 2021, then spiked by 42.78% to $38.1 million in 2022, then surged by 62.02% to $61.8 million in 2023, then decreased by 23.62% to $47.2 million in 2024, then decreased by 16.90% to $64.8 million in 2025.
  • Its Finished Goods was $64.8 million in Q3 2025, compared to $71.0 million in Q2 2025 and $61.4 million in Q1 2025.